These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 27893709)

  • 21. Benzopyran derivative CDRI-85/287 induces G2-M arrest in estrogen receptor-positive breast cancer cells via modulation of estrogen receptors α- and β-mediated signaling, in parallel to EGFR signaling and suppresses the growth of tumor xenograft.
    Saxena R; Fatima I; Chandra V; Blesson CS; Kharkwal G; Hussain MK; Hajela K; Roy BG; Dwivedi A
    Steroids; 2013 Nov; 78(11):1071-86. PubMed ID: 23891847
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Amplification of WHSC1L1 regulates expression and estrogen-independent activation of ERα in SUM-44 breast cancer cells and is associated with ERα over-expression in breast cancer.
    Irish JC; Mills JN; Turner-Ivey B; Wilson RC; Guest ST; Rutkovsky A; Dombkowski A; Kappler CS; Hardiman G; Ethier SP
    Mol Oncol; 2016 Jun; 10(6):850-65. PubMed ID: 27005559
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epigenetic reprogramming of breast cancer cells by valproic acid occurs regardless of estrogen receptor status.
    Travaglini L; Vian L; Billi M; Grignani F; Nervi C
    Int J Biochem Cell Biol; 2009 Jan; 41(1):225-34. PubMed ID: 18789398
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Estrogen Receptor Cofactor SPEN Functions as a Tumor Suppressor and Candidate Biomarker of Drug Responsiveness in Hormone-Dependent Breast Cancers.
    Légaré S; Cavallone L; Mamo A; Chabot C; Sirois I; Magliocco A; Klimowicz A; Tonin PN; Buchanan M; Keilty D; Hassan S; Laperrière D; Mader S; Aleynikova O; Basik M
    Cancer Res; 2015 Oct; 75(20):4351-63. PubMed ID: 26297734
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HOXB7 Is an ERα Cofactor in the Activation of HER2 and Multiple ER Target Genes Leading to Endocrine Resistance.
    Jin K; Park S; Teo WW; Korangath P; Cho SS; Yoshida T; Győrffy B; Goswami CP; Nakshatri H; Cruz LA; Zhou W; Ji H; Su Y; Ekram M; Wu Z; Zhu T; Polyak K; Sukumar S
    Cancer Discov; 2015 Sep; 5(9):944-59. PubMed ID: 26180042
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Functional genomics identifies a mechanism for estrogen activation of the retinoic acid receptor alpha1 gene in breast cancer cells.
    Laganière J; Deblois G; Giguère V
    Mol Endocrinol; 2005 Jun; 19(6):1584-92. PubMed ID: 15831516
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Estrogen receptor alpha inhibits p53-mediated transcriptional repression: implications for the regulation of apoptosis.
    Sayeed A; Konduri SD; Liu W; Bansal S; Li F; Das GM
    Cancer Res; 2007 Aug; 67(16):7746-55. PubMed ID: 17699779
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Histone acetyltransferase MOF is involved in suppression of endometrial cancer and maintenance of ERα stability.
    Wu Y; Zeng K; Wang C; Wang S; Sun H; Liu W; Wang X; Niu J; Cong SY; Zhou X; Zhao Y
    Biochem Biophys Res Commun; 2019 Feb; 509(2):541-548. PubMed ID: 30598260
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.
    Kuske B; Naughton C; Moore K; Macleod KG; Miller WR; Clarke R; Langdon SP; Cameron DA
    Endocr Relat Cancer; 2006 Dec; 13(4):1121-33. PubMed ID: 17158758
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of BTF3 sensitizes luminal breast cancer cells to PI3Kα inhibition through the transcriptional regulation of ERα.
    Ding J; Wang X; Zhang Y; Sang X; Yi J; Liu C; Liu Z; Wang M; Zhang N; Xue Y; Shen L; Zhao W; Luo F; Liu P; Cheng H
    Cancer Lett; 2019 Jan; 440-441():54-63. PubMed ID: 30315845
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bioactive dietary supplements reactivate ER expression in ER-negative breast cancer cells by active chromatin modifications.
    Meeran SM; Patel SN; Li Y; Shukla S; Tollefsbol TO
    PLoS One; 2012; 7(5):e37748. PubMed ID: 22662208
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Estrogen receptor α (ERα) mediates 17β-estradiol (E2)-activated expression of HBO1.
    Wang WZ; Liu HO; Wu YH; Hong Y; Yang JW; Liu YH; Wu WB; Zhou L; Sun LL; Xu JJ; Yun XJ; Gu JX
    J Exp Clin Cancer Res; 2010 Nov; 29(1):140. PubMed ID: 21040551
    [TBL] [Abstract][Full Text] [Related]  

  • 33. AIB1:ERα transcriptional activity is selectively enhanced in aromatase inhibitor-resistant breast cancer cells.
    O'Hara J; Vareslija D; McBryan J; Bane F; Tibbitts P; Byrne C; Conroy RM; Hao Y; Gaora PÓ; Hill AD; McIlroy M; Young LS
    Clin Cancer Res; 2012 Jun; 18(12):3305-15. PubMed ID: 22550166
    [TBL] [Abstract][Full Text] [Related]  

  • 34. OCT-4: a novel estrogen receptor-α collaborator that promotes tamoxifen resistance in breast cancer cells.
    Bhatt S; Stender JD; Joshi S; Wu G; Katzenellenbogen BS
    Oncogene; 2016 Nov; 35(44):5722-5734. PubMed ID: 27065334
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel role for PINX1 as a coregulator of nuclear hormone receptors.
    Noriega-Reyes MY; Rivas-Torres MA; Oñate-Ocaña LF; Vallés AJ; Baranda-Avila N; Langley E
    Mol Cell Endocrinol; 2015 Oct; 414():9-18. PubMed ID: 26187699
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dependence receptor UNC5A restricts luminal to basal breast cancer plasticity and metastasis.
    Padua MB; Bhat-Nakshatri P; Anjanappa M; Prasad MS; Hao Y; Rao X; Liu S; Wan J; Liu Y; McElyea K; Jacobsen M; Sandusky G; Althouse S; Perkins S; Nakshatri H
    Breast Cancer Res; 2018 May; 20(1):35. PubMed ID: 29720215
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CARM1 is an important determinant of ERα-dependent breast cancer cell differentiation and proliferation in breast cancer cells.
    Al-Dhaheri M; Wu J; Skliris GP; Li J; Higashimato K; Wang Y; White KP; Lambert P; Zhu Y; Murphy L; Xu W
    Cancer Res; 2011 Mar; 71(6):2118-28. PubMed ID: 21282336
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chromatin landscape and endocrine response in breast cancer.
    Magnani L; Brunelle M; Gévry N; Lupien M
    Epigenomics; 2012 Dec; 4(6):675-83. PubMed ID: 23244312
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activity of the antiestrogenic cajanin stilbene acid towards breast cancer.
    Fu Y; Kadioglu O; Wiench B; Wei Z; Wang W; Luo M; Yang X; Gu C; Zu Y; Efferth T
    J Nutr Biochem; 2015 Nov; 26(11):1273-82. PubMed ID: 26365581
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Estrogen induces expression of BCAS3, a novel estrogen receptor-alpha coactivator, through proline-, glutamic acid-, and leucine-rich protein-1 (PELP1).
    Gururaj AE; Peng S; Vadlamudi RK; Kumar R
    Mol Endocrinol; 2007 Aug; 21(8):1847-60. PubMed ID: 17505058
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.